KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Tax Provisions (2024 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Tax Provisions for 2 consecutive years, with $2.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Tax Provisions rose 170.15% year-over-year to $2.2 million, compared with a TTM value of $3.5 million through Dec 2025, up 83.19%, and an annual FY2025 reading of $3.5 million, up 83.19% over the prior year.
  • Tax Provisions was $2.2 million for Q4 2025 at Biocryst Pharmaceuticals, up from -$769000.0 in the prior quarter.
  • Across five years, Tax Provisions topped out at $2.2 million in Q4 2025 and bottomed at -$769000.0 in Q3 2025.